6,169 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Purchased by Smith Group Asset Management LLC

Smith Group Asset Management LLC acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 6,169 shares of the medical instruments supplier's stock, valued at approximately $573,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LMAT. Vanguard Group Inc. raised its position in LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier's stock valued at $87,914,000 after buying an additional 38,303 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in LeMaitre Vascular by 18.6% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 6,342 shares of the medical instruments supplier's stock worth $421,000 after buying an additional 993 shares in the last quarter. Congress Wealth Management LLC DE boosted its stake in shares of LeMaitre Vascular by 27.8% during the 1st quarter. Congress Wealth Management LLC DE now owns 98,986 shares of the medical instruments supplier's stock worth $6,569,000 after buying an additional 21,532 shares during the last quarter. Albion Financial Group UT boosted its stake in shares of LeMaitre Vascular by 5.6% during the 1st quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier's stock worth $264,000 after buying an additional 212 shares during the last quarter. Finally, Norden Group LLC acquired a new stake in shares of LeMaitre Vascular in the first quarter valued at about $401,000. 84.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. StockNews.com cut LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Tuesday, August 27th. JMP Securities upped their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 20th. Barrington Research reissued an "outperform" rating and issued a $92.00 price objective on shares of LeMaitre Vascular in a research report on Friday, September 20th. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 target price for the company. Finally, Lake Street Capital started coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a "buy" rating and a $105.00 price target for the company. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $94.67.

Insider Activity at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares of the company's stock, valued at approximately $1,158,335.98. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.79% of the stock is currently owned by company insiders.

LeMaitre Vascular Stock Up 3.5 %

LMAT traded up $3.09 during trading on Tuesday, reaching $90.41. 126,070 shares of the stock traded hands, compared to its average volume of 122,057. The stock's 50-day moving average is $89.33 and its 200 day moving average is $82.50. LeMaitre Vascular, Inc. has a 12 month low of $45.96 and a 12 month high of $93.32. The stock has a market capitalization of $2.03 billion, a PE ratio of 57.83, a P/E/G ratio of 2.29 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. The company had revenue of $55.85 million during the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. LeMaitre Vascular's revenue for the quarter was up 11.4% on a year-over-year basis. During the same period last year, the firm earned $0.37 EPS. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.86 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were issued a dividend of $0.16 per share. The ex-dividend date was Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.71%. LeMaitre Vascular's payout ratio is 42.38%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.